Momelotinib (Ojjaara, Omjjara)

Momelotinib at a glance

Momelotinib is a Janus kinase inhibitor, usually shortened to JAK inhibitor. Ojjaara and Omjjara are verified brand names for the same active medicine. The reviewed products contain 100 mg, 150 mg or 200 mg per tablet. The usual starting dose is 200 mg once daily, with or without food.

Treatment aims can include reducing spleen-related discomfort and other disease symptoms, while helping some patients with anaemia, a shortage of red blood cells. Benefit varies: transfusions or other supportive care may still be needed. Blood tests and your experience of daily life both help the team assess treatment.

Important risks include infections, low platelets or white cells, bleeding, liver injury and severe skin reactions. Heart or clot symptoms also require attention. Do not stop or restart tablets without a plan from the team; symptoms can flare after interruption.

What momelotinib is and how it works

JAK1 and JAK2 are enzymes involved in signals controlling blood-cell production and inflammation. In myelofibrosis, abnormal signalling and changes in the bone marrow can disrupt healthy blood-cell production. An enlarged spleen may cause discomfort beneath the left ribs or make you feel full after small meals. Momelotinib reduces some of this abnormal signalling.

Momelotinib also inhibits a protein called ACVR1. This can lower hepcidin, a hormone that restricts the availability of iron for making red blood cells. Making more iron available may help anaemia. This mechanism does not mean everyone needs an iron supplement: low haemoglobin can have several causes, and iron should be prescribed only when appropriate.

Your haematologist, a doctor specialising in blood disorders, should explain which symptom or blood-count changes would represent useful benefit for you.

How the team decides whether it is suitable

The specialist considers your diagnosis, the severity of anaemia, transfusion needs, spleen symptoms, blood counts, previous treatment and overall health. Bone-marrow findings and molecular tests may contribute to that assessment. The reviewed prescribing information does not require everyone to have one particular JAK mutation before receiving momelotinib. A mutation result alone cannot select the treatment.

Tell the team about infections, hepatitis B, liver disease, unusual bleeding, heart disease, stroke, blood clots, other cancers and current or previous smoking. Pregnancy, breastfeeding and medicine allergies also affect the assessment. These details help the team weigh likely benefit against the monitoring and risks relevant to you.

An active infection should be treated before momelotinib is started. Uncontrolled liver disease also needs investigation and management. Severe liver impairment requires a lower starting dose. Kidney impairment does not automatically mean the same reduction is needed, but experience in end-stage kidney disease or dialysis is limited. Safety and effectiveness below 18 years have not been established.

Before treatment starts

A full blood count measures red cells, infection-fighting white cells and platelets, which help stop bleeding. Liver tests include enzymes such as ALT and AST, and bilirubin, a substance the liver processes. These baseline results help distinguish an existing problem from a new treatment effect.

Tell the team if you have ever had hepatitis B, even if you currently feel well. The US label describes checking hepatitis B blood markers in patients with HBV infection and obtaining specialist advice when tests suggest current or previous infection. Your team should confirm whether screening, preventive antiviral medicine or closer monitoring is needed. Do not stop an existing hepatitis medicine yourself.

Bring a complete list of prescriptions, shop-bought medicines and supplements. Include cholesterol medicines, epilepsy medicines, diabetes treatment and herbal products. If you are switching from another JAK inhibitor, obtain precise stop-and-start instructions. European information says momelotinib should not be combined with another JAK inhibitor.

Discuss contraception, possible pregnancy and fertility preservation before treatment. The European patient leaflet says a pregnancy test may be requested. Have a thermometer, your hospital's urgent contact details and a clear plan for illness outside clinic hours. Ask how repeat prescriptions will be arranged so an avoidable supply gap does not interrupt treatment.

How treatment is taken

Daily dose and swallowing

Take your prescribed dose once daily at about the same time, with or without food. Swallow tablets whole with water. Do not cut, crush or chew them. The 200 mg tablet is capsule-shaped but is still a tablet; its appearance does not mean it can be opened.

The usual starting dose is 200 mg daily. The reviewed labels use 150 mg daily for severe liver impairment. Side effects may lead to a supervised pause or reduction, often in 50 mg steps using the available strengths. Treatment is discontinued if 100 mg daily cannot be tolerated.

Treatment can continue while its benefits outweigh its risks, with regular specialist assessment. There is no single fixed course length for everyone.

Check the strength whenever a new bottle arrives. If swallowing is difficult or you use a feeding tube, contact the specialist pharmacist. The reviewed labels do not provide a home dispersion or tube-administration method. Do not make a liquid by crushing tablets or copy instructions from another medicine.

Missed dose, vomiting and an extra dose

If you miss a dose, skip it and take the next scheduled dose the following day. Do not take two doses together or add a catch-up dose later.

If you vomit just after taking a tablet, do not take another one. Take the next dose at its normal time. Contact the team if vomiting continues, fluids will not stay down or you are becoming dizzy or passing little urine. If you accidentally take more than prescribed, seek medical advice immediately and keep the bottle available to identify the dose.

Storage and handling

Keep tablets in the original bottle, protected from moisture, with the lid securely closed. Leave the moisture-absorbing desiccant inside; it is not medicine and must not be swallowed. US storage specifies 20–25°C (68–77°F), with excursions to 15–30°C (59–86°F). European information gives no special temperature requirement. Follow your own pack, particularly during hot-weather travel.

Keep the bottle away from children. Ask the pharmacist before transferring tablets to a pill organiser because the original moisture-protective packaging is required. Return unwanted tablets through the pharmacy or treating hospital. The tablets contain lactose: tell the pharmacist about diagnosed sugar-intolerance disorders rather than assuming every digestive symptom is due to lactose.

Monitoring and checking whether treatment is working

Blood counts are checked before treatment and periodically afterwards, with extra tests when clinically needed. Low platelets may increase bleeding risk; low neutrophils, a type of white cell, can increase infection risk. The dose decision considers your starting platelet count as well as the current result. Do not interpret one number using another patient's dose plan.

US guidance specifies liver tests before treatment, monthly for the first six months, then periodically as clinically indicated. European information specifies baseline and periodic tests without that fixed monthly schedule. Follow the schedule your team gives you; liver injury can appear on a blood test before you notice symptoms.

The team also reviews haemoglobin, transfusion requirements, spleen-related symptoms, fatigue and daily functioning. Examination, symptom records and imaging when appropriate help assess response. Improvement in one area may occur without the same change in every other measure.

Report bleeding, infections, skin changes, numbness, dizziness, blurred vision and any new medicines between visits. A lower dose or temporary hold can be a safety measure rather than evidence that treatment has failed. Planned withdrawal needs supervision because a sudden symptom flare can occur.

Common side effects and practical management

Diarrhoea, nausea and abdominal discomfort

Tell the team about new diarrhoea and use anti-diarrhoea treatment only according to their plan. Drink regularly within any fluid restriction. Frequent loose stools, worsening abdominal pain, fever, blood in the stool or difficulty drinking need prompt advice. Infection can also cause diarrhoea, so do not assume every episode is a harmless tablet effect.

Smaller meals and prescribed anti-sickness treatment may make nausea easier to manage. Keep a record if symptoms repeatedly follow your dose. Persistent vomiting or reduced urine needs assessment for dehydration. Constipation can also occur; ask for a suitable bowel plan, especially if anti-sickness medicines contribute.

An enlarged spleen can cause abdominal symptoms as well as treatment itself. Tell the team where the discomfort is, whether it is new, and whether eating worsens it. Sudden severe pain or pain with faintness needs urgent assessment rather than repeated painkillers at home.

Tiredness, headache and dizziness

Fatigue can reflect the illness, anaemia, infection, sleep disruption or treatment. Balance rest with gentle activity when you feel able, and ask for help with demanding tasks. Report a marked change, especially with breathlessness, palpitations or fever. Blood tests may identify a treatable contributor.

Dizziness, low blood pressure and occasionally fainting can occur. Rise slowly from a chair or bed and sit down if light-headed. Do not drive or operate machinery while dizzy or with blurred vision. Recurrent episodes, a fall, chest discomfort or a racing heartbeat need medical assessment.

Report persistent headaches rather than repeatedly adding painkillers. Aspirin and anti-inflammatory medicines may increase bleeding concerns when platelets are low. The team can recommend a suitable option. A sudden severe headache with weakness, confusion or a vision change is an emergency.

Skin changes, tingling and other effects

A mild rash or itch may respond to gentle skin care and a recommended moisturiser. Photograph a changing rash if practical, but do not let this delay assessment. Painful skin, blisters, peeling or sores affecting the mouth or eyes are different from a mild rash and require immediate help.

Report new numbness, burning, tingling or weakness in hands or feet. These symptoms can affect balance and everyday tasks. Vitamin B1 deficiency is also listed in the product information, but this is not a reason to start high-dose supplements or assume every nerve symptom has that cause. The clinician decides which assessment is appropriate.

Important risks and serious side effects

Infection and hepatitis B reactivation

Infections can be serious or fatal. Contact the hospital urgently for fever, chills, a new cough, breathlessness, painful urination, a painful spreading skin area or feeling suddenly very unwell. Serious infection is possible without a high temperature. Severe breathing difficulty, confusion or collapse needs emergency care.

Report a painful blistering rash that might be shingles promptly, particularly near an eye. Blood counts do not explain every infection risk, so a recent acceptable result should not delay a call. Preventive antibiotics or antivirals depend on your individual history and the whole treatment plan; they are not a standard prescription for everyone.

Hepatitis B may become active again during JAK-inhibitor treatment. This can happen with or without obvious symptoms. Patients with chronic infection need treatment and monitoring according to hepatitis guidance, and positive markers may require liver-specialist advice about prevention versus surveillance. Attend these appointments even when you feel well.

Low platelets, low neutrophils and bleeding

A low platelet count is called thrombocytopenia. Report unusual bruising, pinpoint red or purple spots, persistent nosebleeds, bleeding gums or blood in urine. Black stools, vomiting blood, uncontrolled bleeding or a severe headache after a head injury needs emergency assessment.

Low neutrophils are called neutropenia. They can make an infection more dangerous. The team may pause or reduce momelotinib until counts recover. Do not independently add aspirin to prevent clots: bleeding and clotting risks need a combined assessment, especially if you already use an anticoagulant.

Liver injury

Liver inflammation or injury may cause yellow eyes or skin, dark urine, unusual tiredness, loss of appetite or pain beneath the right ribs. Contact the team promptly. These symptoms can have other causes, including hepatitis reactivation, and need investigation.

Significant blood-test changes may require a hold and a lower restart dose after recovery. Recurrent substantial liver-enzyme elevations can require permanent discontinuation. Avoid starting herbal “liver cleansing” products; they may introduce further risks or interactions.

Severe skin or allergic reactions

The current US label warns about severe skin reactions, including toxic epidermal necrolysis, in which skin can blister and peel. A painful spreading rash, peeling, or sores involving the mouth or eyes requires immediate medical assessment. Do not take the next dose while urgently seeking instructions. The team should interrupt treatment while the cause is investigated; a severe or life-threatening skin reaction attributed to momelotinib requires permanent stopping without re-exposure.

Swelling of the lips, tongue or throat, trouble breathing or collapse may indicate a severe allergic reaction. Call local emergency services. This urgent situation takes priority over routine advice about gradually stopping treatment.

Heart events, clots and other cancers

Labels discuss heart attacks, strokes, blood clots and additional cancers partly because another JAK inhibitor showed increased risks in certain patients with rheumatoid arthritis. Those results cannot be treated as a measured risk of the same size for momelotinib in myelofibrosis. European information notes that events have been reported with momelotinib but a causal relationship has not been established. Individual risk assessment still matters.

Seek emergency care for chest pressure, sudden breathlessness, coughing blood, facial drooping, one-sided weakness or difficulty speaking. A newly painful swollen limb needs urgent assessment for a clot. Tell the team about smoking, previous vascular problems and any new lump or persistent skin change. Do not stop an effective treatment solely because you have read a class warning; discuss what it means for your situation.

Other medicines, supplements and vaccinations

Momelotinib affects proteins that transport medicines through the body. It can raise exposure to rosuvastatin, a cholesterol medicine. US guidance starts rosuvastatin at 5 mg and limits it to 10 mg daily when used together. The prescriber must review an existing prescription; do not make the change yourself. European information also advises monitoring rosuvastatin and other sensitive BCRP substrates, such as sulfasalazine.

Ciclosporin and other OATP1B1/1B3 transporter inhibitors can increase momelotinib exposure, requiring closer observation and sometimes dose adjustment. European information additionally advises checking medicines such as metformin, theophylline and tizanidine. Carry an updated list rather than relying on a short list of examples to exclude every interaction.

European guidance recommends extra monitoring of disease symptoms with strong CYP3A4-inducing medicines such as carbamazepine, phenytoin, phenobarbital or St John's wort because effectiveness may decrease. Do not abruptly stop an epilepsy medicine. US clinical studies did not show a significant overall effect with the tested repeated rifampicin schedule; this does not mean all enzyme-inducing combinations can be treated identically.

Ask the pharmacist about your complete prescription, including hormonal contraception. Discuss vaccination before booking it: suitability and timing, particularly for live vaccines, depend on your immune status and other treatment.

Everyday life during treatment

A daily reminder and a simple symptom record can help. Note missed doses, transfusions and important changes in energy, appetite or abdominal fullness. Bring the record to appointments.

Maintain regular meals and fluids within any medical restriction. Ask for dietitian support if early fullness or nausea makes eating difficult. Do not start iron simply because anaemia is present. Gentle activity may support stamina, but pace it around symptoms and avoid activities likely to cause injury if platelets are low.

Discuss flexible work, help at home and transport if dizziness or fatigue affects safety. Tell your dentist about treatment and blood-count changes before a procedure. Hand hygiene and prompt reporting of infection symptoms remain useful even when treatment is taken entirely at home.

Plan travel around monitoring and adequate medicine supply. Keep tablets in their original bottle and carry your prescription and urgent contact details. Ask for emotional support when uncertainty, persistent symptoms or repeated transfusions are affecting sleep and relationships.

Fertility, contraception, pregnancy and breastfeeding

Momelotinib may harm a developing baby. Patients who could become pregnant should use highly effective contraception during treatment and for at least one week after the last dose. European guidance adds a barrier method when using systemic hormonal contraception because its effectiveness may be reduced. Confirm a method suitable for you before starting.

European Omjjara information contraindicates treatment during pregnancy; the US label allows use only when expected maternal benefit outweighs fetal risk. If pregnancy is suspected or confirmed, contact the treating team immediately for a treatment decision. Do not wait until a routine appointment.

Do not breastfeed during treatment. US instructions continue this restriction for at least one week afterwards. European information prohibits breastfeeding during treatment without specifying the same post-treatment interval. Agree the restart date with the team, taking any accompanying medicine into account.

The reviewed labels do not specify a fixed male contraception interval. Discuss plans for a family with the team; animal studies found effects on male and female fertility, but effects in people are unknown. Preservation options are best discussed before treatment, rather than assuming fertility will be unaffected.

After a pause or the end of treatment

A treatment change must have a written plan. The current US label warns that symptoms of myeloproliferative disease can flare after JAK inhibitors, including momelotinib, are interrupted or stopped. Reported severe problems after JAK-inhibitor withdrawal include fever, respiratory distress, low blood pressure, abnormal widespread clotting and organ failure.

For a planned interruption that is not due to a potentially life-threatening toxicity, the clinician may consider gradually reducing the dose. Do not devise your own taper or restart schedule. Severe allergic or skin reactions and other emergencies may require an immediate hold instead; urgent assessment should not be delayed to taper.

After stopping, continue agreed blood tests, symptom follow-up, hepatitis monitoring and reproductive precautions. If symptoms flare, clinicians investigate other illnesses as well and may consider supervised restarting when appropriate. Feeling better does not by itself establish that restarting is safe. Return unused tablets only after the treatment plan is clear.

Frequently asked questions